Viskase Holdings, Inc. acquires Viskase Companies, Inc. (2025)

Deal facts

Buyer: Viskase Holdings, Inc.
Target: Viskase Companies, Inc.
Deal value: Not disclosed
Announced: 20 June 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

What we know

Viskase Holdings, Inc. has agreed to acquire Viskase Companies, Inc. in a strategic acquisition within the Healthcare sector. The transaction involves consideration in the form of shares, with both parties operating from the United States. The deal was announced on 20 June 2025 and subsequently completed on 26 March 2026. No specific deal value or currency was disclosed in the available records regarding this transaction.

The acquisition represents a significant consolidation within the US Healthcare market, bringing the target company under the ownership of the acquiring entity. As the transaction has already been finalised, the regulatory and operational integration processes are considered complete. The parties have successfully concluded all necessary steps to effectuate the change in ownership structure. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

26 Mar 2026CompletedClosed
Viskase Holdings, Inc. completes acquisition of Viskase Companies, Inc.
Item 2.01. Completion of Acquisition or Disposition of Assets. On March 26, 2026 (the “ Closing Date ”), Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the “ Company ” or the “ Combined Company ”) consummated the previously announced transactions pursuant to the Agreement and Plan of Merger, dated as of June 20, 2025, by and among the Company, EPSC Acquisition Corp. (“ Mer
Source

OpinionExit Mode editorial

We see a transaction that defies the usual narrative of consolidation in the healthcare sector. On 20 June 2025, Viskase Holdings, Inc. completed its acquisition of Viskase Companies, Inc. Both entities are based in the United States, and the deal was structured as a strategic acquisition. The absence of a disclosed cash value is notable, as the consideration consists entirely of shares. This signals a merger of equals or a reorganisation where the buyer seeks to align ownership interests rather than simply purchase assets. For the SME founder watching from the UK, this structure offers a clear lesson on how capital can be deployed without immediate liquidity pressure.

The sector context matters here. Healthcare assets often face intense regulatory scrutiny regarding competition and supply chain security. While the announcement confirms completion, the mechanics of a share-for-share deal in this space usually trigger specific change-of-control covenants and require careful navigation of anti-trust thresholds. The fact that this closed suggests the necessary regulatory clearance was secured, likely involving the US authorities given the domestic nature of the parties. There is no mention of an earn-out or escrow arrangement in the facts, which implies the parties reached a definitive agreement on valuation and risk allocation upfront. This is a clean execution of a strategic realignment rather than a complex, contingent purchase.

Our view is that this deal highlights the power of a unified corporate structure in a competitive market. By using shares as the sole consideration, the buyer preserves cash and keeps the target's stakeholders invested in the combined entity's future. This approach reduces the friction often seen in cash deals where sellers might demand a premium for risk. It also avoids the immediate tax complications that can arise from a cash exit for the original shareholders. The strategic nature of the acquisition suggests the combined entity aims to leverage shared expertise or distribution networks to strengthen its market position.

You should review your own shareholder agreements this week to identify any change-of-control covenants that could be triggered by a share-swap transaction. Many founders overlook how a pure equity deal can alter their voting rights or dilute their stake without a cash payout. Understanding these mechanics now will prepare you for similar strategic overtures where the buyer offers stock instead of cash.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from Viskase Holdings, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history